1. Home
  2. WWR vs MDCX Comparison

WWR vs MDCX Comparison

Compare WWR & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WWR

Westwater Resources Inc.

HOLD

Current Price

$0.53

Market Cap

82.3M

ML Signal

HOLD

MDCX

Medicus Pharma Ltd.

HOLD

Current Price

$0.45

Market Cap

18.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
WWR
MDCX
Founded
1977
2008
Country
United States
United States
Employees
N/A
16
Industry
Metal Mining
Sector
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
82.3M
18.1M
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
WWR
MDCX
Price
$0.53
$0.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$1.92
$14.50
AVG Volume (30 Days)
895.1K
1.6M
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.47
$0.25
52 Week High
$3.75
$3.69

Technical Indicators

Market Signals
Indicator
WWR
MDCX
Relative Strength Index (RSI) 44.75 67.48
Support Level $0.47 $0.38
Resistance Level $0.72 $0.52
Average True Range (ATR) 0.03 0.04
MACD 0.01 0.01
Stochastic Oscillator 52.96 86.72

Price Performance

Historical Comparison
WWR
MDCX

About WWR Westwater Resources Inc.

Westwater Resources Inc is an energy technology company focused on developing battery-grade natural graphite materials through a vertically integrated, mine-to-market strategy anchored by its two primary projects in Coosa County, Alabama: the Kellyton Graphite Plant and the Coosa Graphite Deposit. Westwater also holds mineral rights to explore and mine the Coosa Graphite Deposit, which Westwater anticipates will eventually provide natural graphite flake concentrate as feedstock to the Kellyton Graphite Plant.

About MDCX Medicus Pharma Ltd.

Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.

Share on Social Networks: